Abstract:Schematic diagram depicting proposed mechanisms of PKM2‐induced renal pericyte‐myofibroblast transdifferentiation through regulation of transcription levels of downstream LDHA and GLUT1 and lactate production. GLUT1, glucose transporter 1; LDHA, lactate dehydrogenase A; PKM2, pyruvate kinase M2; TGFβ1, transforming growth factor β1. We aimed to investigate the role of renal pericyte pyruvate kinase M2 (PKM2) in the progression of acute kidney injury (AKI) to chronic kidney disease (CKD). The role of PKM2 in renal pericyte‐myofibroblast transdifferentiation was investigated in an AKI‐CKD mouse model. Platelet growth factor receptor beta (PDGFRβ)‐iCreERT2; tdTomato mice were used for renal pericyte tracing. Western blotting and immunofluorescence staining were used to examine protein expression. An 5‐ethynyl‐2′‐deoxyuridine assay was used to measure renal pericyte proliferation. A scratch cell migration assay was used to analyse cell migration. Seahorse experiments were used to examine glycolytic rates. Enzyme‐linked immunoassay was used to measure pyruvate kinase enzymatic activity and lactate concentrations. The PKM2 nuclear translocation inhibitors Shikonin and TEPP‐46 were used to alter pericyte transdifferentiation. In AKI‐CKD, renal pericytes proliferated and transdifferentiated into myofibroblasts and PKM2 is highly expressed in renal pericytes. Shikonin and TEPP‐46 inhibited pericyte proliferation, migration, and pericyte‐myofibroblast transdifferentiation by reducing nuclear PKM2 entry. In the nucleus, PKM2 promoted downstream lactate dehydrogenase A (LDHA) and glucose transporter 1 (GLUT1) transcription, which are critical for glycolysis. Therefore, PKM2 regulates pericyte glycolytic and lactate production, which regulates renal pericyte‐myofibroblast transdifferentiation. PKM2‐regulated renal pericyte‐myofibroblast transdifferentiation by regulating downstream LDHA and GLUT1 transcription and lactate production. Reducing nuclear PKM2 import can reduce renal pericytes‐myofibroblasts transdifferentiation, providing new ideas for AKI‐CKD treatment.

Search progress of pyruvate kinase M2 (PKM2) in organ fibrosis

Pyruvate Kinase M2 Regulates Fibrosis Development And Progression By Controlling Glycine Auxotrophy In Myofibroblasts

Targeting pyruvate kinase M2 for the treatment of kidney disease

Extracellular PKM2 Facilitates Organ-Tissue Fibrosis Progression.

Pyruvate Kinase M2 Tetramerization Protects Against Hepatic Stellate Cell Activation and Liver Fibrosis.

Pyruvate kinase M2 regulates kidney fibrosis through pericyte glycolysis during the progression from acute kidney injury to chronic kidney disease

Pyruvate Kinase M2 Mediates Fibroblast Proliferation to Promote Tubular Epithelial Cell Survival in Acute Kidney Injury.

Enhanced glycolysis in the process of renal fibrosis aggravated the development of chronic kidney disease.

PKM2: A Potential Regulator of Cardiac Injury Through Glycolytic and Non-glycolytic Pathways

Therapeutic Targeting of PKM2 Ameliorates NASH Fibrosis Progression in A Macrophage-Specific and Liver-Specific Manner

PKM2 Promotes Pulmonary Fibrosis by Stabilizing TGF-β1 Receptor I and Enhancing TGF-β1 Signaling.

Pyruvate Kinase M2 Modulates the Glycolysis of Chondrocyte and Extracellular Matrix in Osteoarthritis

Pyruvate kinase M2 activation protects against the proliferation and migration of pulmonary artery smooth muscle cells

Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics

PKM2, function and expression and regulation

Recent Advances on PKM2 Inhibitors and Activators in Cancer Applications.

PKM2 in carcinogenesis and oncotherapy

PKM2 Coordinates Glycolysis with Mitochondrial Fusion and Oxidative Phosphorylation

The Role of PKM2 in the Regulation of Mitochondrial Function: Focus on Mitochondrial Metabolism, Oxidative Stress, Dynamic, and Apoptosis. PKM2 in Mitochondrial Function

The role of PKM2 in cancer progression and its structural and biological basis

Mutation of regulatory phosphorylation sites in PFKFB2 worsens renal fibrosis